Thermo Fisher Scientific Inc (NYSE:TMO) was upgraded by equities research analysts at Cleveland Research from a “neutral” rating to a “buy” rating in a research report issued on Thursday.

A number of other equities research analysts also recently commented on the stock. Barclays PLC restated an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday. Wells Fargo & Company restated an “outperform” rating and issued a $200.00 price objective (up previously from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 price objective for the company in a research report on Tuesday, July 11th. BidaskClub upgraded shares of Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Finally, Citigroup Inc. restated a “buy” rating and issued a $201.00 price objective (up previously from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. One research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $187.29.

Shares of Thermo Fisher Scientific (NYSE TMO) traded up 1.024% during trading on Thursday, hitting $181.995. The stock had a trading volume of 392,512 shares. The stock has a market cap of $71.20 billion, a price-to-earnings ratio of 33.199 and a beta of 1.06. The stock’s 50-day moving average is $176.10 and its 200-day moving average is $162.04. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $182.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 26th. The medical research company reported $2.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.02 by $0.06. Thermo Fisher Scientific had a return on equity of 15.73% and a net margin of 11.58%. The firm had revenue of $4.77 billion for the quarter, compared to analyst estimates of $4.68 billion. During the same quarter last year, the company posted $1.80 earnings per share. The business’s revenue was up 10.9% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific will post $9.23 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc (NYSE:TMO) Upgraded at Cleveland Research” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/20/thermo-fisher-scientific-inc-nysetmo-upgraded-at-cleveland-research.html.

In related news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the transaction, the chief financial officer now directly owns 37,790 shares in the company, valued at approximately $6,660,865.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas W. Loewald sold 1,532 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $168.76, for a total value of $258,540.32. Following the transaction, the insider now owns 41,277 shares of the company’s stock, valued at $6,965,906.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,720 shares of company stock valued at $4,960,764. Insiders own 0.49% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Street Advisors Inc. NC increased its position in shares of Thermo Fisher Scientific by 2.9% in the first quarter. Franklin Street Advisors Inc. NC now owns 19,994 shares of the medical research company’s stock valued at $3,071,000 after buying an additional 565 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $1,135,000. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $1,805,000. Kentucky Retirement Systems bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $4,045,000. Finally, Whalerock Point Partners LLC increased its position in shares of Thermo Fisher Scientific by 21.6% in the fourth quarter. Whalerock Point Partners LLC now owns 2,815 shares of the medical research company’s stock valued at $398,000 after buying an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 86.93% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.